Literature DB >> 28089695

The pharmacology of tacrine at N-methyl-d-aspartate receptors.

Martin Horak1, Kristina Holubova2, Eugenie Nepovimova3, Jan Krusek1, Martina Kaniakova1, Jan Korabecny3, Ladislav Vyklicky1, Kamil Kuca3, Ales Stuchlik1, Jan Ricny2, Karel Vales2, Ondrej Soukup4.   

Abstract

The mechanism of tacrine as a precognitive drug has been considered to be complex and not fully understood. It has been reported to involve a wide spectrum of targets involving cholinergic, gabaergic, nitrinergic and glutamatergic pathways. Here, we review the effect of tacrine and its derivatives on the NMDA receptors (NMDAR) with a focus on the mechanism of action and biological consequences related to the Alzheimer's disease treatment. Our findings indicate that effect of tacrine on glutamatergic neurons is both direct and indirect. Direct NMDAR antagonistic effect is often reported by in vitro studies; however, it is achieved by high tacrine concentrations which are not likely to occur under clinical conditions. The impact on memory and behavioral testing can be ascribed to indirect effects of tacrine caused by influencing the NMDAR-mediated currents via M1 receptor activation, which leads to inhibition of Ca2+-activated potassium channels. Such inhibition prevents membrane repolarization leading to prolonged NMDAR activation and subsequently to long term potentiation. Considering these findings, we can conclude that tacrine-derivatives with dual cholinesterase and NMDARs modulating activity may represent a promising approach in the drug development for diseases associated with cognitive dysfunction, such as the Alzheimer disease.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cognition; Long term potentiation; M1 activation; Multi-target directed ligands; NMDA receptors; Tacrine

Mesh:

Substances:

Year:  2017        PMID: 28089695     DOI: 10.1016/j.pnpbp.2017.01.003

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  14 in total

1.  Biocomputational Screening of Natural Compounds against Acetylcholinesterase.

Authors:  Syed Sayeed Ahmad; Mohd Babu Khan; Khurshid Ahmad; Jeong-Ho Lim; Sibhghatulla Shaikh; Eun-Ju Lee; Inho Choi
Journal:  Molecules       Date:  2021-04-30       Impact factor: 4.411

2.  New cyclopentaquinoline hybrids with multifunctional capacities for the treatment of Alzheimer's disease.

Authors:  Kamila Czarnecka; Małgorzata Girek; Karolina Maciejewska; Robert Skibiński; Jakub Jończyk; Marek Bajda; Jacek Kabziński; Przemysław Sołowiej; Ireneusz Majsterek; Paweł Szymański
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

3.  Development of 2-Methoxyhuprine as Novel Lead for Alzheimer's Disease Therapy.

Authors:  Eva Mezeiova; Jan Korabecny; Vendula Sepsova; Martina Hrabinova; Petr Jost; Lubica Muckova; Tomas Kucera; Rafael Dolezal; Jan Misik; Katarina Spilovska; Ngoc Lam Pham; Lucia Pokrievkova; Jaroslav Roh; Daniel Jun; Ondrej Soukup; Daniel Kaping; Kamil Kuca
Journal:  Molecules       Date:  2017-07-28       Impact factor: 4.411

Review 4.  Profiling donepezil template into multipotent hybrids with antioxidant properties.

Authors:  Eva Mezeiova; Katarina Spilovska; Eugenie Nepovimova; Lukas Gorecki; Ondrej Soukup; Rafael Dolezal; David Malinak; Jana Janockova; Daniel Jun; Kamil Kuca; Jan Korabecny
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

5.  Exploring Structure-Activity Relationship in Tacrine-Squaramide Derivatives as Potent Cholinesterase Inhibitors.

Authors:  Barbora Svobodova; Eva Mezeiova; Vendula Hepnarova; Martina Hrabinova; Lubica Muckova; Tereza Kobrlova; Daniel Jun; Ondrej Soukup; María Luisa Jimeno; José Marco-Contelles; Jan Korabecny
Journal:  Biomolecules       Date:  2019-08-19

6.  Synthesis and bioevaluation of new tacrine-cinnamic acid hybrids as cholinesterase inhibitors against Alzheimer's disease.

Authors:  Yao Chen; Jie Zhu; Jun Mo; Hongyu Yang; Xueyang Jiang; Hongzhi Lin; Kai Gu; Yuqiong Pei; Liang Wu; Renxiang Tan; Jing Hou; Jingyi Chen; Yang Lv; Yaoyao Bian; Haopeng Sun
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

Review 7.  Memantine Derivatives as Multitarget Agents in Alzheimer's Disease.

Authors:  Giambattista Marotta; Filippo Basagni; Michela Rosini; Anna Minarini
Journal:  Molecules       Date:  2020-09-02       Impact factor: 4.411

8.  Pursuing the Complexity of Alzheimer's Disease: Discovery of Fluoren-9-Amines as Selective Butyrylcholinesterase Inhibitors and N-Methyl-d-Aspartate Receptor Antagonists.

Authors:  Jan Konecny; Anna Misiachna; Martina Hrabinova; Lenka Pulkrabkova; Marketa Benkova; Lukas Prchal; Tomas Kucera; Tereza Kobrlova; Vladimir Finger; Marharyta Kolcheva; Stepan Kortus; Daniel Jun; Marian Valko; Martin Horak; Ondrej Soukup; Jan Korabecny
Journal:  Biomolecules       Date:  2020-12-22

9.  Region-Specific and Age-Dependent Multitarget Effects of Acetylcholinesterase Inhibitor Tacrine on Comprehensive Neurotransmitter Systems.

Authors:  Elva Fridjonsdottir; Theodosia Vallianatou; Ioannis Mantas; Reza Shariatgorji; Anna Nilsson; Luke S Schembri; Luke R Odell; Per Svenningsson; Per E Andrén
Journal:  ACS Chem Biol       Date:  2021-12-21       Impact factor: 5.100

Review 10.  A review of the mechanisms underlying selected comorbidities in Alzheimer's disease.

Authors:  Karolina Maciejewska; Kamila Czarnecka; Paweł Szymański
Journal:  Pharmacol Rep       Date:  2021-06-13       Impact factor: 3.024

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.